Human enhancement drugs and the pursuit of perfection
DOI:
https://doi.org/10.20882/adicciones.89Keywords:
enhancement, public health, lifestyle, anabolic, drugs marketAbstract
The emerging threat to public health posed by the use of human enhancement drugs has remained largely unrecognised. In attempts tobecome stronger, happier or smarter, or to look thinner, younger or morebeautiful, people are turning to a diverse range of pharmaceuticals. Thewidespread availability of drugs with the potential to improve humanattributes, appearance and abilities has generated a new and growingaudience of users. Unlike users of drugs such as heroin, cocaine etc,users of human enhancement drugs do not necessarily perceive themselves as ‘drug users’. Those attracted to these drugs may have little or no knowledge or understanding of the physical or psychological harm associated with these substances or their potential for addiction. In addition to the potent effects of many human enhancement drugs, there are considerable risks associated to the clandestine nature of the market. The growing number of untested, banned or adulterated drugs and the lack of safeguards and quality assurance in the illicit manufacturing process has resulted in serious harms and fatalities. The ease with which pharmaceuticals can be manufactured and distributed, combined with the significant profits that can be made from the illicit market, has resulted in a growing challenge for policy makers and health systems in many countries. This editorial aims to raise awareness of this emerging drugs situation and provide a brief overview of some of the drugs and their associated risks.References
Berridge, V. (1978). Victorian opium eating: responses to opiate use in
nineteenth-century England. Victorian Studies, 21, 437-461.
British Medical Association (1909). Secret remedies. What they cost and what they contain. London: British Medical Association.
Chan, T. Y. K. (2009) Outbreaks of severe hypoglycaemia due to illegal sexual enhancement products containing undeclared glibenclamide. Pharmacoepidemiology & Drug Safety, 18, 1.250–1.251.
Conrad, P. (2007) The medicalization of society: on the transformation
of human conditions into treatable disorders. Baltimore: Johns Hopkins University Press.
Evans–Brown, M., Dawson, R. T., Chandler, M., & McVeigh, J. (2009)
Use of melanotan I and II in the general population. BMJ, 338:b566.
Evans–Brown, M. & McVeigh, J. (2009) Injecting human growth hormone as a performance- enhancing drug—perspectives from the United Kingdom. Journal of Substance Use, 14, 267–288.
Evans–Brown, M., Kimergård, A., & McVeigh, J. (2009) Elephant in the room? The methodological implications for public health research of performance–enhancing drugs derived from the illicit market. Drug Test Analysis, 1, 323–326.
Evans-Brown, M., McVeigh, J., Perkins, C., & Bellis, M. A. (2012) Human
enhancement drugs: The emerging challenges to public health. Liverpool: Public Health Observatories in England.
Fraser, R., Gower, D. B., Honour, J. W., Ingram, M. C., Kicman, A. T.,
Makin, H. L. J., & Stewart, P. M. (2010) Analysis of corticosteroids. Steroid Analysis (2nd Edition). Springer.
Geiling, E. M. K., & Cannon, P. R. (1938) Pathologic effects of elixir of sulfanilamide (diethylene glycol poisoning). A clinical and experimental correlation: final report. JAMA, 111, 919-26.
Lau, G., Lo, D. S., Yao, Y. J., Leonh, H. T., Chan, C. L., & Chu, S. S.(2004) A fatal case of hepatic failure possibly induced by nitrosofenfluramine: a case report. Medicine, Science and the Law, 44, 252-63.
National Audit Office (2003), Safety, quality, efficacy: regulating medicines in the UK. London: The Stationery Office.
Oliveira, D. B., Foster, G., Savill, J., Syme, P. D., & Taylor, A. (1987)
Membranous nephropathy caused by mercury–containing skin lightening cream. Postgraduate Medical Journal, 63, 303-304.
Savulescu, J., ter Meulen, R., & Kahane, G. (Eds) (2011) Enhancing human capacities. Oxford: Wiley-Blackwell.
Schnetzler, G., Banks, I., Kirby, M., Zou, K. H., & Symonds, T. (2010)
Characteristics, behaviors, and attitudes of men bypassing the healthcare system when obtaining phosphodiesterase type 5 inhibitors. Journal of Sexual Medicine, 7, 1237-46.
‘Stalinon’: a therapeutic disaster (1958) BMJ. 1:515. Working Party on Amphetamine Preparations (1968). Report of the Working Party on amphetamine preparations. British Medical Association: London.
World Health Organization (2004) WHO medicines strategy 2004–2007. Countries at the core. Geneva: World Health Organization. World Health Organization (2007) Quality Assurance of Pharmaceuticals: A Compendium of Guidelines and Related Materials, Volume 2, Good Manufacturing Practices and Inspection (2nd edit.). Geneva: World Health Organization.
Young, J. H. (1992) The medical messiahs: a social history of health quackery in Twentieth–Century America. Princeton: Princeton University Press.
